A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma

Gilead Sciences29 enrolled

Overview

To treat patients with scleroderma by blocking the expression of LOXL2. The investigators first need to confirm (through observation) that LOXL2 is overexpressed in disease.

Scleroderma is a chronic skin-hardening disease. There are two types of scleroderma. The first type is called limited cutaneous scleroderma, where disrupted blood flow causes skin discoloration and sometimes patients experience high blood pressure in their arteries. The second type is called diffuse cutaneous scleroderma and it is much more aggressive, affecting a larger area of skin causing organ damage. This study will determine if the disease is associated with an elevated expression of LOXL2 levels in tissue samples from patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Limited Scleroderma Diffuse Scleroderma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Over 18 years of age * Documented diagnosis of scleroderma * Willing and able to provide written informed consent Exclusion Criteria: * Use of experimental therapies within 28 days prior to Screening. * Aspirin use \> 81 mg daily within 1 week prior to Screening. * Any lab abnormality or concurrent medical condition that, in the opinion of the investigator would make the patient ineligible for the study

Locations (1)

St Vincent's Centre for Applied Medical Research

Darlinghurst, New South Wales, Australia

Outcomes

Primary Outcomes

Summarized the number and percentage of subjects with elevated LOXL2 levels

Time frame: Baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.